1130 POSTER Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC): results of a randomised phase II trial

首页> 外文期刊>European Journal of Cancer Supplements >1130 POSTER Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC): results of a randomised phase II trial

【24h】

1130 POSTER Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC): results of a randomised phase II trial

机译：1130 POSTER多西他赛/吉西他滨与序贯方案（包括顺铂/吉西他滨/多西他赛）在IV期非小细胞肺癌（NSCLC）患者的一线治疗中的比较：一项II期随机试验的结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 1130 POSTER Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC): results of a randomised phase II trial [J] . European Journal of Cancer Supplements . 2005,第2期

机译：1130 POSTER多西他赛/吉西他滨与序贯方案（包括顺铂/吉西他滨/多西他赛）在IV期非小细胞肺癌（NSCLC）患者的一线治疗中的比较：一项II期随机试验的结果
2. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial [J] . D. Binder, H. Schweisfurth, C. Grah, Cancer Chemotherapy and Pharmacology . 2007,第1期

机译：多西他赛/吉西他滨或顺铂/吉西他滨再多西他赛在转移性非小细胞肺癌（NSCLC）患者的一线治疗中：一项多中心随机II期试验的结果
3. 1129 POSTER Sequential versus concomitant administration of docetaxel and gemcitabine as first-line treatment of advanced non-small cell lung cancer (NSCLC): results of a phase II/III randomised study [J] . European Journal of Cancer Supplements . 2005,第2期

机译：1129 POSTER多西紫杉醇和吉西他滨序贯治疗与同时给药作为晚期非小细胞肺癌（NSCLC）的一线治疗：II / III期随机研究的结果
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment [O] . F M Wachters, H J M Groen, B Biesma, 2005

机译：多西紫杉醇与多西紫杉醇和伊立替康的II期随机试验用于一线治疗失败的IIIb–IV期非小细胞肺癌患者
7. 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC) [O] . L. Paz-Ares, M.A. Socinski, J. Shahidi, 2016

机译：1320_pr：表皮生长因子受体（EGFR）患者的亚群分析 - 表达肿瘤患者：一种随机，多中心，开放标签，吉西拜齐铂（GC）加上Necitumumab（N）对GC的第一个研究阶段鳞状非小细胞肺癌（SQ-NSCLC）的患者（PTS）治疗患者（PTS）治疗

1130 POSTER Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC): results of a randomised phase II trial

著录项

相似文献

相关主题

期刊订阅